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ABSTRACT
Human herpes virus 6 (HHV6) is known to reactivate after hematopoietic stem cell transplantation (HSCT), and
has been suggested to be associated with severe clinical manifestations in adults. The clinical significance in chil-
dren remains unclear.We investigated the incidence of HHV6 reactivation in relation toHSCT-associatedmor-
bidity andmortality in children. Between January 2004 andMay 2006, 58 pediatric patients, median age 7.6 years
(range: 0.1-18.1 years), received their first allogeneic HSCT. After HSCT, HHV6, Epstein Barr Virus (EBV),
cytomegalovirus (CMV), and adenovirus (AdV)-plasma loads were weekly measured by quantitative PCR. Clin-
ical features, engraftment, graft-versus-host disease (GVHD), and HSCT-associated mortality and morbidity
were monitored. HHV6 reactivations were classified in group I (no reactivation), group II (loads\1000 cp/
mL) and group III (loads .1000 cp/mL). CMV, EBV, Herpes Simpex Virus, Varicella Zoster Virus, and AdV-
reactivations were treated according to local guidelines. HHV6 was treated only when there was clinical suspi-
cion of disease. Thirty-six HLA-identical and 22 HLA nonidentical grafts were transplanted of which 43 were
bone marrow or peripheral blood stem cells grafts and 15 were cord blood (CB) grafts. Median follow-up of
the patients was 15.5 (1-35) months. HHV6 reactivation occurred in 39 of 58 (67%) patients with 31 of 39
(80%) occurring within the first 30 days post-HSCT. In 26 of 58 (45%) patients (group III), HHV 6 reactivation
was significantly associated with higher nonrelapse mortality (P5 .02), usingmultivariate Cox proportional haz-
ard models and grade 2-4 acute GVHD (P 5 .03) and chronic GVHD (P 5 .05) in a multivariate logistic regres-
sion analysis. HHV6 reactivation is very common after HSCT in children and is associated with serious
transplantation-related morbidity and mortality. Although the exact role of HHV6 reactivation after HSCT
has to be elucidated, early detection and initiation of therapy might be of benefit.
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Viral reactivations are major complications after
allogeneic hematopoietic stem cell transplantation
(HSCT), and are suggested to be associated with acute
graft-versus-host Disease (aGVHD), allograft rejec-
tions, and increasednonrelapsemortality (NRM) [1-3].
The compromised immune system in allogeneic
HSCT recipients, because of both the administrationof serotherapy (eg, ATG) and immunosuppressive
drugs to prevent and/or treat GVHD and rejection
of the donor graft after HSCT, make the patient
more susceptible and vulnerable for viral reactivations.
With the progress in molecular and immune diagnos-
tics, better monitoring of viral reactivation allow to
further examine the potential role of Human Herpes
virus type 6 (HHV6) reactivation in morbidity and
outcome.831
832 P. J. Anne de Pagter et al.The role of HHV6 after HSCT has not been in-
vestigated in detail.
In the healthy population, HHV6 infection is
recognized as the cause of a febrile disease in early
childhood and exanthem subitum. Over 90% of the
population is infected within the first 18 months of
life [4,5]. Based on the age of the transplanted patients,
it is to be expected that almost all HSCT patients have
been infected with HHV6 preceding HSCT treat-
ment.
In a prospective study among adult HSCT pa-
tients, a strong association between HHV6 reactiva-
tion and the occurrence of grade 3-4 GVHD, central
nervous system (CNS) dysfunction, as well as in-
creased mortality has been described [6]. In children,
the association with clinical outcome is largely
unknown, although HHV-6 reactivation is reported
[7-9]. Better insight in the role of HHV-6 reactivation
may lead to better preventive and therapeutic options
and decrease the incidence of HHV6-associated com-
plications after HSCT. Therefore, we studied the inci-
dence of HHV6 reactivation and its association with
clinical outcome in pediatric HSCT recipients.
METHODS
Study Design, Study Population, and Data
Collection
A prospective cohort study of clinical outcome in
children after HSCT was performed. The exposed
group was defined as patients with plasma HHV6
DNA positivity, and the unexposed group consisted
of patients without HHV6 DNA positivity.
All children (0-18 years) who received a first alloge-
neic-HSCT, irrespective of the indication, between Jan-
uary 2004 and May 2006, in the University Medical
Center ofUtrechtwere included.Transplantation char-
acteristics, data of engraftment (neutrophils and plate-
lets), GVHD features, viral reactivations, as well as
transplantation-associated morbidity were registered.
Patientswere enrolled in the SCTand researchprotocol
after the patients or parents had provided written in-
formed consent. The study was approved by the Ethics
Committee of the University Medical Center of
Utrecht. Within this prospective cohort study, charac-
teristics of the studied patients are shown in Table 1.
Viral Load Monitoring, Diagnostics, and Technique
Viral serology. Cytomegalovirus (CMV), Epstein
Barr Virus (EBV), herpes simplex virus (HSV), and
varicella zoster virus (VZV) serostatus of HSCT-re-
cipients (IgM and IgG) were determined prior to
HSCT treatment by means of immunofluorescence
(IF) or ELISA technique [10]. Because of the high in-
cidence of primary infection in early life (.90% at the
age of 1.5 years), we assumed that virtually all of our
recipients and donors (except cord blood donors)were considered seropositive for HHV6 and Adenovi-
rus [4,5].
Viral monitoring. From January 2004, all HSCT
patients were weekly monitored by quantitative real-
time PCR for plasma viral load of EBV, CMV, and
Adenovirus during the first 4 months after HSCT.
From April 2005, HHV-6 was added to this weekly vi-
ral monitoring protocol. In retrospect, HHV6 DNA
load was measured in all previously collected samples
from January 2004 until April 2005. For VZV and
HSV, PCR on vesicle swabs was only performed in
the case of clinical suspicion of associated disease. In
the case of hemorrhagic cystitis, BK- and JC-DNA
loads were measured in urine samples.
Quantitative real-time PCR (qPCR). For
HHV6, we used a newly developed quantitative real-
time PCR assay. DNA was extracted from EDTA
plasma samples using MagnaPure system and Total
Nucleic Acid isolation kits (Roche, Almere, TheNeth-
erlands). Amplification ofHHV6DNAwas performed
using real-time PCR (ABI Prism 7900 HT; Applied
Biosystem, Foster City, CA). The forward (50-GAA
GCA GCA ATC GCA ACA CA-30) and reverse (50-
ATG TAA CTC GGT GTA CGG TGT YA-30)
primers and probe (50-Fam-AAC CCG TGC GCC
GCT-Tamra-30) were located in the DNA polymerase
gene, which encodes HHV6 tegument protein [11].
The primers and probe were kindly provided by
H.G.M. Niesters et al. (Department of Virology,
EMC, Rotterdam, The Netherlands).
The viral load was calculated by plotting the Ct-
value observed in the clinical sample on a standard
curve of an electron microscopy counted HHV6 strain
(Advanced Biotechnologies Incorporated, Columbia,
MD). The limit of quantitation (LOQ) of this assay
was 1000 cp/mL. Below this LOQ, positive results
could be detected, but accurate quantitation of these
results was unreliable. The lower limit of detection
for these qualitative results was approximately 250
cp/mL. For the detection of EBV and CMV a compa-
rable real-time PCR assay was used, as previously de-
scribed, with a detection limit of 50 cp/mL [12,13].
For Adenovirus (type A, B, C, D, E, and F), we also
developed a new real-time quantitative PCR assay,
with primers: 50-TTT GAG GTG GAY CCM ATG
GA-30, 50-TTT GAG GTY GAY CCC ATG GA-30,
50-AGA ASG GSG TRC GCA GGT A-30, 50-AGA
ASG GTG TRC GCA GAT A-30 and probes: 50-Fam
-ACC ACG TCG AAA ACT TCG AA-MGB-30, 50-
Fam-ACC ACG TCG AAA ACT TCA AA-MGB-30
and 50-Fam-ACA CCG CGG CGT CA-MGB-30.
The detection limit was 100 cp/mL.
In the case of suspicion of disease, real-time PCR
was performed in urine samples for BK-virus DNA
and JC-virus DNA and in skin lesion samples for
VZV DNA and HSV DNA, as previously described
[13-16]. For BK-virus, a new real-time quantative











Median age at SCT (range) in year 7.6 (0.1-18.1) 7 (0.1-17.1) 9 (2.4-17.2) 4.9 (1.3-18.1) NS
Median follow up (range) in mths 15.5 (1-35) 17.5 (1.5-35.5) 27.5 (5-34.5) 10.5 (1-34) NS
Median HHV6 reactivation time (days)* 16 (0-120) N/A 20 (1-120) 14 (0-106) NS
N (%) N (%) N (%)
Gender
Male 33 9 (47) 9 (69) 15 (58) NS
Female 25 10 (53) 4 (31) 11 (42)
Indication
Malignant 28 8 (42) 8 (62) 12 (46) NS
Nonmalignant 30 11 (58) 5 (38) 14 (54)
HLA-disparity†
Matched 36 11 (58) 11 (85) 14 (54) NS
Mismatched 22 8 (42) 2 (15) 12 (46)
Donor
Family 17 7 (37) 5 (39) 5 (19) NS
Unrelated 41 12 (63) 8 (61) 21 (81)
Source
BM 37 11 (58) 12 (92) 14 (54) NS
CB‡ 15 6 (32) — 9 (35)
PBSC 6 2 (10) 1 (8) 3 (12)
Conditioning
TBI based 18 5 (26) 7 (54) 6 (23) NS
Chemobased 40 14 (74) 6 (46) 20 (77)
N indicates number of patients; SCT, stem cell transplantation; N/A, not applicable; HLA, human leukocyte antigen; BM, bone marrow;
CB, cord blood; PBSC, peripheral blood stem cells; TBI, total-body irradiation.
*Median reactivation time after HCT.
†Matched was defined when either 10 out of 10 molecularly typed alleles were matched for bone marrow or PBSC or 6 out of 6 for cord bloods
(CB) based on Rubinstein criteria.
‡All cord bloods were unrelated.PCR assay was developed, with primers: 50-TGCTGA
TAT TTG TGG SCT GTT TACTA-30, 50-CTC
AGG CGR ATC TTA AAA TAT CTT G-30 and
probes: 50-Fam-CAG CTC TGG AAC ACA ACA
GTG GAG AGG C-Tamra-30, 50-Fam-CAG CTC
TGGGACACAACAGTGGAGAGGC-Tamra-30.
Conditioning Regimens, Supportive Care, and
Treatment
All patients received either a chemotherapy based
or total-body irradiation (TBI)- based myeloablative
conditioning regimen. Recipients of an unrelated do-
nor received serotherapy with antithymocyte globulin
(ATG)-rabbit (Genzyme, Fresenius). As supportive
care patients received antiemetic drugs (Ondansetron)
and prophylactic anticonvulsive therapy (clonazepam)
during busulfan gifts. Antimicrobial prophylaxis was
administered according to the institutional protocol:
ciprofloxin and fluconazol from the start of ablative
medication until the end of the neutropenic period,
which was defined as\500 neutrophils/mL; cefuroxim
from day 0 until the end of the neutropenic period and
cotrimoxazol from day128 after HSCT. Patients who
were seropositive for HSV prior to HSCT receivedprophylactic treatment of low-dose acyclovir (500
mg/m2/day) until at least day 160 after HSCT.
Cyclosporine A (dosis based on plasma levels of
100-200 mg/L) was given to all patients as GVHD
prophylaxis. Recipients of matched sibling donor cells
received cyclosporine A as a single agent, in recipients
of unrelated marrow donor cells methotrexate (short
course: 10 mg/m2 on days 11, 13, and 16 after
HSCT) was added, whereas in cord blood recipients
prednisolon (1 mg/kg until day 128 after HSCT,
with a taper in 14 days) was added. Furthermore,
cord blood recipients were treated with filgrastim
from day17 after HSCT until neutrophils were above
2000/mL.
(Preemptive) antiviral therapy. Preemptive
treatment with ganciclovir for CMV reactivations
was initiated when the CMV DNA load exceeded
1000 cp/mL. When neutrophils were below 2000/mL
or when ganciclovir treatment was not effective, fosca-
vir was prescribed.
Recipients of EBV-seronegative transplants (in-
cluding cord blood recipients) were preemptively
treated with rituximab (course of 4 gifts) when EBV
DNA load exceeded 1000 cp/mL in 2 consecutive
measurements. Other patients with plasma EBV
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occurred, which were thought to be associated with
EBV-posttransplant lymphoproliferative disorder.
Adenovirus reactivation was treated with cidofovir
when the Adeno DNA load exceeded 1000 cp/mL in
2 consecutive measurements. VZV and HSV reactiva-
tions were treated with aciclovir or valaciclovir.
Patients with BK- or JC-virus reactivations received
hyperhydration as supportive care. Patients with
HHV6 reactivation were treated with foscavir in the
case of high clinical suspicion of HHV6-associated
disease (eg, encephalitis, colitis).
Clinical Variables
HLA-matching was based on high-resolution
(HR)-typing for class I and class II (10 antigens: A, B,
C,DR, andDQ) for bonemarrow (BM) and peripheral
blood stem cell (PBSC) donors. For cord blood (CB)-
donors intermediate resolution criteria were used
(Loci A and B by intermediate resolution and DRB1
by HR typing) [17]. A DPB1 mismatch was not taken
into account. For the analyses, patients were divided
into a matched or mismatched group. Identical CB
grafts, according to the intermediate resolution criteria
mentioned above, were considered as matched. Other
factors taken into account were cell source (BM 1
PBSC or CB), donor relationship, conditioning regi-
men (chemotherapy-based or TBI-based) and indica-
tion for HSCT (malignant or nonmalignant).
Endpoints and Definitions
Primary endpoints for the analyses were associations
of HHV6 reactivation with ‘‘event-free survival’’
(EFS), survival, and NRM with a follow-up of at least
12 months. An event was defined as relapse or graft
failure. NRM was defined as all causes of mortality,
except relapse.
Secondary endpoints were aGVHD and chronic
GVHD (cGVHD), multiple viral reactivations, and
graft failure.
With respect to HHV6 reactivation, patients were
divided into 3 groups, based on maximum HHV6
DNA load: patients with no HHV6 reactivation, pa-
tients with HHV6 DNA load between 250 and 1000
cp/mL and patients with HHV6 DNA load exceeding
1000 cp/mL during the follow-up period, in line with
previous studies [6]. A HHV6 reactivation episode was
defined as .1 consecutive HHV6 positive sample.
Acute GVHD was diagnosed and graded accord-
ing to Glucksberg et al. [18]. Severity of cGVHD
was graded according to Shulman et al. [19]. A clinical
relevant viral reactivation was defined as plasma DNA
loads exceeding 1000 cp/mL of EBV, CMV, or Adeno-
virus, or clinical suspicion of HSV, VZV, BK virus, or
JC virus, subsequently confirmed by PCR. ‘‘Multiple
viral reactivations’’ was defined as 2 or more viral reac-tivations or clinical viral diseases (except HHV6) in
a patient during follow-up.
The definition of engraftment was: platelet en-
graftment .50,000 platelets/mL without transfusion
for 1 week, neutrophil engraftment .500 neutro-
phils/mL for 3 consecutive days, and leukocyte engraft-
ment .1000 leukocytes/mL for 3 consecutive days.
Chimerism was measured by monitoring variable
number tandem repeats (VNTRs) by fluorescent
primer-based PCR genotyping. Full donor chimerism
was defined as having a donor chimerism of .95%.
Statistical Analysis
Analyses of the associations between the various
variables and the ‘‘endpoints’’ were performed using
Cox proportional hazards models. Univariate predic-
tors of outcome that were statistically significant
(P-value\.05) were selected for multivariate Cox pro-
portionale hazards models. Results are expressed as
hazard ratios (HR) and their corresponding 95% con-
fidence intervals (95% CI).
For analyses of the secondary endpoints, univariate
andmultivariate logistic regression analyses were used.
Dichotomous outcomes (eg, EFS: yes/no) were used as
dependent variables and predictors as independent
variables. Univariate predictors of outcome that were
statistically significant (P-value \.10), were selected
for multivariate logistic regression analysis. Results
are expressed as odds ratios (OR) and their corre-
sponding 95% CI. CIs not including 1 (P-values
\.05) were considered statistically significant. Statisti-
cal analysis was performed using SPSS version 12.01.
RESULTS
Patient Characteristics and General Results
Fifty-eight patients received a first HSCT with
a median age at transplantation of 7.6 years (range:
0.1-18.1 years). Patient characteristics are shown in
Table 1. The first sample was included prior to
HSCT and we obtained a.95% compliance in weekly
sampling after HSCT. We included 4 patients under
the age of 1.5 years. These patients might be seroneg-
ative. In these patients, HHV6 reactivation after
HSCT did not occur. Overall, HHV6 DNA was de-
tected in plasma of 39 of 58 (67%) patients, CMV
DNA in 19 of 58 (33%) patients, EBV DNA in 28 of
58 (48%) patients, Adenovirus DNA in 13 of 58
(22%) patients (Figure 1), VZV DNA in 9 of 58
(16%) patients, HSV DNA in 3 of 58 (5%) patients,
BK virus in 16 of 58 (28%) patients, and JC virus in
1 of 58 (2%) patients. The median time to HHV6 re-
activation was 16 days afterHSCT (range: 0-120 days):
a median time of 14 days was observed in the patients
with viral load exceeding 1000 cp/mL, compared to 20
days in the patients with viral load below 1000 cp/mL).
For CMV reactivation, the median time to reactivation
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Figure 1. DNA loads of viral reactivations after HSCT. #Fifteen of 58 patients were CMV seropositive and had a CMV-seropositive donor
(D1R1), 14 of 58 were CMV seropositive but had a CMV seronegative donor (D2R1), 8 of 58 patients were CMV seronegative but had
CMV a seropositive donor (D1R2), and 21/58 patients were CMV seronegative with a seronegative donor (D2R2). *Twenty-eight of 58 pa-
tients were EBV D1R1, 11 of 58 patients were D2R1, 8 of 58 patients were D1R2, and 11 of 58 patients were D2R2. U Based on the lit-
erature, we suspect all patients to be Adenovirus seropositive. Gender, indication, donor type, cell source, conditioning regimen, and HLA-
matching did not significantly differ between patients at risk or not at risk for viral reactivation after HSCT. Additionally, 18 of 58 patients
were at risk for HSV reactivation and 36 of 58 recipients were at risk for VZV reactivation.was 19 days (range: 0-170 days), for EBV 47 days
(range: 4-219 days), for Adenovirus 53 days (range:
28-226 days) (Figure 1). Longer median times and
ranges were observed for HSV, VZV, BK virus, and
JC virus. For HSV, the median time was 82 days
(range: 49-99 days), for VZV 120 days (range: 34-
309 days), and for BK virus 100 days (10-441 days).
With respect to the HHV6 reactivation, in 31 of 39
(80%) HHV6 reactivated patients this occurred within
the first 30 days post-HSCT. The median HHV6
DNA load was 1828 cp/mL (range: 250-2,2.106 cp/
mL). Antiviral (prophylactic) treatment did not signif-
icantly differ between the HHV6 DNA load groups.
Three of 58 patients were suspected for HHV-6 dis-
ease and were treated with foscavir (1 for encephalitis,
2 for fever of unknown origin associated with skin rash
and with secondary neutropenia). All treated patients
had HHV-6 DNA load exceeding 10,000 copies/mL.
All 3 recovered from suspected HHV-6 disease and
DNA load decreased below 1000 cp/mL, but 2 pa-
tients died of a transplantation related cause (infection
and GVHD).
HHV6 Reactivation and Primary Endpoints
To analyze the association between HHV6 reacti-
vation and EFS, univariate Cox proportional hazard
models were performed for HHV6 DNA load, age,
gender, indication for SCT, HLA disparity, donor-
type, cell source, and conditioning regimen (Table
2). In the multivariate Cox proportional hazard model
with variables HHV6 DNA load and cell source,
HHV6 DNA load exceeding 1000 copies/mL was as-
sociated (‘‘borderline significance’’) with the endpoint
EFS (HR 2,3; 95% CI 0.9-6.2, P 5 .086) and survival
(HR 3,7; 95% CI 1.0-13.2, P 5 .044). Because of the
‘‘borderline significance’’ for EFS, we additionally an-
alyzed the linear trend over all categories for HHV6
DNA loads using a multivariate Cox proportional haz-ard model. The found ‘‘borderline’’ association turned
out to be significant (HR 1.7; 95% CI 1.1-2.8,
P 5 .047) in this analysis. These data suggest that in-
creasing the number of patients included will probably
lead to a significant association between HHV6 DNA
load exceeding 1000 copies/mL and EFS. TheKaplan-
Meier survival curve shows a poor survival for patients
withHHV6DNA load exceeding 1000 cp/mL in com-
parison to the other 2 groups (Figure 2). Eighteen of
58 patients deceased after HSCT, of whom 15 (83%)
patients had an HHV6 reactivation (Table 3). In the
multivariate Cox proportional hazard model, HHV6
DNA load exceeding 1000 cp/mL was significantly
associated with NRM at 1 year after HSCT (HR 5.2;
95% CI 1.2-23.3, P 5 .031). Age, gender, indication
for SCT, HLA disparity, donor type, cell source, and
conditioning, were not significantly associated.
HHV6 Reactivation and Secondary Endpoints
GVHD. Overall, aGvHD was noted in 16 of 58
(28%) patients. In univariate logistic regression analy-
sis, HHV6 reactivation with a DNA load exceeding
1000 cp/mL (OR 5.3; 95% CI 1.1-28.0; P 5 .049),
conditioning with TBI (OR 0.2; 95% CI 0.1-0.7;
P 5 .014) and malignancy as indication for HSCT
(OR 0.21; 95% CI 0.1-0.8; P 5 .02) were predictors
for aGVHD. Age, gender, HLA matching, donor
type, and donor source were not significantly associ-
ated. In the multivariate logistic regression model,
HHV6 reactivation with DNA load exceeding 1000
cp/mL remained the only independent predictor for
aGVHD (OR 7.8; 95% CI 1.2-50.1; P 5 .032).
Chronic GVHD occured in 14 of 43 (32.6%) patients
at risk (8 with limited and 6 with extensive GVHD). In
univariate analyses, HHV6 reactivation with DNA
load exceeding 1000 cp/mL was found to be the only
predictor for cGVHD (OR 5.1; 95% CI 1.03-25.1;
P 5 .046). Age, gender, indication, HLA disparity,
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Event-Free Survival Survival
N total N % HR 95% CI P-Value N % HR 95% CI P-Value
Overall 58 34 59 40 69
Age 58 1.0 0.9-1.0 0.225 1.0 0.9-1.1 0.601
Gender
Male 33 20 61 1 24 73 1
Female 25 14 56 1.1 0.5-2.4 0.845 16 64 1.3 0.5-3.1 0.597
Indication
Malignant 28 16 57 1 18 64 1
Non malignant 30 18 60 1.1 0.5-2.3 0.891 22 73 0.9 0.3-2.1 0.733
HHV6
Negative\250 cp/mL 19 13 68 1 16 84 1
Positive 250-1000 cp/mL 13 9 69 0.8 0.2-3.0 0.799 10 77 1.2 0.2-6.1 0.805
Positive . 1000 cp/mL 26 12 45 2.5 0.9-6.4 0.067 14 54 4.0 1.1-14.1 0.031
Donor
Family 17 12 71 1 13 77 1
Unrelated 41 22 54 1.6 0.6-4.1 0.302 27 66 1.3 0.5-3.7 0.575
Cell source
Bone marrow/PBSC 43 28 65 1 32 74 1
Cord blood 15 6 40 2.2 1.0-5.1 0.058 8 53 2.3 0.9-5.9 0.080
Conditioning
TBI 18 13 72 1 14 78 1
Chemobased 40 21 53 0.4 0.2-1.2 0.094 26 65 0.5 0.2-1.5 0.196
HLA-disparity
Matched 36 23 64 1 27 75 1
Mismatched 22 11 50 1.4 0.6-2.9 0.457 13 60 1.6 0.6-3.9 0.326
Acute-GVHD
No 42 24 57 1 30 71 1
Yes 16 10 63 0.8 0.3-2.1 0.690 10 63 1.2 0.5-3.2 0.700
N indicates number of patients; OR, odd ratio; CI, confidence intervals; HLA disparity, human leukocyte antigens disparity; BM, bone marrow;
CB, cord blood; TBI, total-body irradiation; GVHD, graft-versus-host disease.donor type, donor source, and type of conditioning,
did not show significant associations with cGVHD.
Multiple viral reactivations were seen in 8 of 26
(38%) patients with HHV6 DNA load exceeding
1000 cp/mL compared to 8 of 32 (31%) patients
with low HHV6 DNA load or no HHV6 reactivation.
Patients at risk for multiple viral reactivations
Figure 2. Kaplan-Meier survival curve after HSCT.(Figure 1) did not significantly differ between the
HHV6 DNA load groups.
Engraftment. Neutrophil and platelet engraft-
ment did not differ between the 3 HHV6 DNA load
groups. Overall, neutrophil engraftment occurred at
a median time of 20 days (range: 7-60 days) after
HSCT and platelet engraftment at a median time of
31 days (range: 11-417 days) after HSCT.
DISCUSSION
This is the first pediatric HSCT study in which
quantitative, plasma-based real-time HHV6 PCR re-
sults were associated with clinical outcome. In our pe-
diatric allogeneic hematopoietic cell transplantation
population, HHV6 reactivation was observed in as
high as 67% of patients. In 45% of the patients, the
HHV6 DNA load exceeded 1000 cp/mL. A high
HHV6 DNA load was an independent predictor of
aGVHD and cGVHD, and lower survival rates,
mainly because of NRM.
Despite the relatively low number of patients,
these results are in line with the results found in studies
in adults [6,20]. In the prospective study of Zerr et al.
[6], HHV6 reactivation was observed in 47% of 110
adult patients and was significantly associated with se-
vere GvHD (grade 3-4) and all-cause mortality.











Relapse 2 1 (5) 1(8)
Nonrelapse mortality
Multiorgan failure 3 3(12)
Infection 5 1(5) 4(16)
GvHD 3 1(8) 2(8)
Cardiopulmonal failure 5 1(5) 1(8) 3(12)
Table shows number of patients (%).Hentrich et al. [20] reported a similar association with
severe GVHD, but not with mortality. In contrast to
the earlier mentioned studies in adults and some
smaller case series, we did not observe any significant
association with CNS dysfunction or delayed platelet
engraftment [21-23].
In other studies, albeit in adults, similar high
HHV6 reactivations rates (48%-72%) were observed,
but without any association with increasedGVHD and
NRM [21,22,24]. However, comparing these studies
in adults with our findings, we have to take into ac-
count that the HHV6 PCR assay is not internationally
standardized and that different samples (eg, whole
blood samples or plasma) are used, potentially leading
to different HHV6 DNA loads. In addition, the
HHV6 loads in the adult population seem to be lower
compared to the HHV6 DNA loads in children after
HSCT. In these adult studies, higher HHV6 DNA
loads were not separately analyzed.
Furthermore, the more frequently used non mye-
loablative (NMA) conditioning in adults compared
with children may influence the outcome as well.
Moreover, in our pediatric study population,most chil-
dren were treated with cord blood cells or bone mar-
row-derived stem cells, whereas in the adult
population, the majority is treated with peripheral
blood stem cells. The higher HHV6 DNA load in
cord blood recipients, as previously reported in the lit-
erature, may be because of the absence of adaptive im-
munity against HHV6 in cord blood [22,25-27].
Finally, children have had a primary HHV6 infection
more recently compared with adults, and therefore,
they may have a less extensive immunity and higher
HHV6 DNA load in case of a reactivation. The lower
median age of the patients with HHV6 DNA load ex-
ceeding 1000 cp/mL compared to the patients without
HHV6 reactivation (Table 1) is in line with this hy-
pothesis, as well are the observations in studies with ad-
enovirus in which lower age was also associated with
higher viral load [1,28-30].
In the prospective part of our study (23 of 58 pa-
tients), 3 patients, clinically suspected of HHV6 dis-
ease, were treated with foscavir. After initiation of
therapy, moderate or severe GVHD was seen in these
patients. Although the antiviral treatment appeared tobe effective, and resulted in a significant decrease in
HHV6 DNA load, it did not prevent the subsequent
death in 2 patients. This may be because of the timing
of the antiviral therapy, which might have been started
too late. Based on only plasma HHV6 DNA load, we
might have underrecognized the frequency of HHV6
disease in tissues (eg, CNS disease), as is also suggested
in other herpes virus reactivations studies after HSCT
[31]. More invasive diagnostics might detect HHV6
more frequently, as described for other viruses as well.
The association of HHV6 reactivation with
aGVHD and cGVHD grade II-IV in our study in chil-
dren is comparable to results in adults [20,21,24]. Al-
though the pathogenesis of GVHD is still unclear,
tissue damage, attributable to previous therapy, under-
lying disease, and conditioning regimens, are assumed
to be the initial trigger for the development of GVHD
[32,33]. As suggested for other virus reactivations
[2,3,28,34], HHV6 reactivation might be a factor en-
hancing tissue damage by inflammatory responses
due the lytic infection and lymphoproliferation [35].
The high frequency of HHV6 DNA positivity
in deceased patients (15 of 18 patients (83%) is
remarkable. All deceased patients with a HHV6
DNA load exceeding 1000 cp/mL deceased because
of NRM. From this study, it is not possible to
determine whether HHV6 reactivation is a cause of
NRM or a marker for other causes of mortality. Inter-
estingly however, 10 of 26 (38%) of the patients with
HHV6 DNA load exceeding 1000 cp/mL, developed
aGVHD within 2 weeks after the start of the HHV6
reactivation, compared to 2 of 19 (11%) of the patients
without HHV6 reactivation developing aGVHD. All
of these patients were on standard immunsuppressive
treatment (GVHD prophylaxis). This suggests that
a HHV6 reactivation occurring so early after HSCT
might be a trigger in the development of GVHD
and other complications by modulated immune recon-
stitution. The association of HHV6 reactivation with
a DNA load exceeding 1000 cp/mL and NRM might
therefore be because of an altered immune reconstitu-
tion caused by HHV6, as suggested in several in vitro
and in vivo studies. HHV6 can interfere with the im-
mune system through a variety of mechanisms. The
CD41 T lymphocyte is the primary target for lytic
838 P. J. Anne de Pagter et al.HHV6 replication [36-38]. Lytic HHV6 infection
could influence these cells and the associated immune
response. In vitro, HHV6 infection results in a loss of
CD46 expression, which can alter the cytokine and
chemokine production [39,40]. By modulating these
specific antiviral immune responses, HHV6 can facil-
itate its own spread and persistence [41].
In conclusion,HHV6reactivationwas frequentlyob-
served in pediatric recipients of allogeneic HSCT and
was associated with poor survival, mainly because of
NRM. Regular HHV6 DNA monitoring after HSCT
is needed to identify the HHV6 reactivation, and this
may act as an early predictor for poor outcome, given
its strong association with GVHD and NRM. Further
elucidation of the role of HHV6 reactivation after
HSCT and the immune response would be needed to
develop more specific treatment regimens and protect
patients fromHHV6associatedmorbidity andmortality.
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